Notice: Fall 2017 exams affected by natural disasters... More >

Expand/Collapse Close

ABIM knows that we have many physicians whose lives have been upended by recent natural disasters. If you live or work near an affected area, we understand that the weather may have impacted your ability to take your Fall 2017 exam as scheduled. We have developed a series of options to help you get through this process as smoothly as possible. If you have any questions, please call us at 1-800-441-ABIM (2246) or email request@abim.org.

American Board of Internal Medicine home page

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Nephrology Board Exam Committee

Talat A. Ikizler, MD, Chair

Dr. Ikizler, a board certified nephrologist, is the Catherine McLaughlin Hakim Chair in Vascular Biology and Professor of Medicine at the Vanderbilt University School of Medicine in Nashville, Tennessee. He is the Associate Director of Division of Nephrology and Director of the Master of Science in Clinical Investigation Program, the most prominent educational platform for clinical translational research at Vanderbilt University.

Between 2000 and 2012, he was the Medical Director and CEO of the Vanderbilt University Medical Center Outpatient Dialysis unit. He maintains an active clinical program both at VU Medical Center and as a staff physician at TN Valley Healthcare System of the Veterans Administration.

As a clinical investigator focused on patient-related outcomes, Dr. Ikizler is the Principal Investigator of a number of ongoing studies aimed at improving the outcomes and quality of life in patient populations ranging from early kidney disease, patients on maintenance dialysis and patients with acute kidney injury. His clinical interest and expertise are focused on the care of the patients with chronic kidney disease, end-stage renal disease on maintenance dialysis and acute kidney injury. He also has a significant research and clinical interest in nutritional and metabolic aspects of acute and chronic disease states. Dr. Ikizler serves as Chair of the American Board of Internal Medicine Nephrology Board Exam Committee.

Dr. Ikizler earned his medical degree from the Istanbul University Faculty of Medicine.

As of January 2017, Dr. Ikizler reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Vanderbilt University, from the following company:

  • Baxter, clinical trial of sodium MRI.

Service on a research-related expert panel or advisory board for the following company, with compensation as listed:

  • Fresenius, a nutrition-related study in kidney patients, receiving reimbursement for travel expenses and honoraria.

Work as an author or editor for following companies, with compensation as listed:

  • Wolters Kluwer, receiving compensation as an editor for handbooks on nutrition and kidney disease.

Dr. Ikizler serves on the board of US Renal Care, receiving reimbursement for travel expenses and monthly compensation.

Dr. Ikizler serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Satellite Health Care, co-Chair of the Scientific Advisory Board, receiving reimbursement for travel expenses and honoraria.

Phyllis August, MD

Dr. August is the Ralph A. Baer MD Professor of Research in Medicine, and a Professor of Medicine, Public Health, and Medicine in Obstetrics and Gynecology at Weill Cornell Medicine. She is an Attending Physician at New York Presbyterian (NYP) Hospital-Weill Cornell, the Director of the NYP-Weill Cornell Hypertension Center, the Program Director for the Nephrology Fellowship training program at NYP Weill Cornell and the Director of the Theresa and Eugene Lang Center for Research and Education at New York Presbyterian Queens. She is board certified in both Internal Medicine and Nephrology.

Dr. August has been involved in clinical practice and clinical investigation related to hypertension, particularly in the context of pregnancy and/or kidney disease for over 30 years. She has been a member of several committees that have developed guidelines for the treatment of these conditions including The American College of Obstetricians and Gynecologist's Task Force, The National High Blood Pressure Education Program Working Group on Hypertension and Pregnancy, and the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure V and VI. Dr. August is an Associate Editor of the Journal of the American Society of Nephrology. She is a member of the American Board of Internal Medicine Nephrology Board Exam Committee and the Medical Board of the Preeclampsia Foundation, and a former member of the Post-Graduate Education Committee for the American Society of Nephrology.

Dr. August received a bachelor's degree in biology from Harvard College, her medical degree from Yale University, and her master's of public health degree from the Harvard School of Public Health. She completed house staff training at Yale New Haven Hospital and the New York Hospital, and a fellowship in nephrology and hypertension at the New York Hospital/Weill Cornell.

As of January 2017, Dr. August reported the following external relationships:

Service on data and safety monitoring boards for the following company, with compensation as listed below:

  • Medtronic, for renal denervation study in patients with treatment-resistant hypertension, receiving honoraria.

Work as an author or editor for the following company, with compensation as listed below:

  • American Society of Nephrology, Associate Editor for the Journal of the American Society of Nephrology, receiving consulting fees.

Michael J. Choi, MD

Dr. Choi, who is board certified in Nephrology, is an Associate Professor of Medicine and Clinical Director of Nephrology at the Johns Hopkins University School of Medicine.

He was the former Nephrology Fellowship Program Director at the Johns Hopkins University School of Medicine.

Dr. Choi is President-Elect of the National Kidney Foundation (NKF) and is a member of the NKF Board of Directors. He is the NKF-Kidney Disease Outcomes Quality Initiative (KDOQI) Vice-Chair of Education. He has served as a committee member for the KDOQI US Commentary on the 2012 Kidney Disease | Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerulonephritis and the KDOQI US Commentary for the Primary Care Practitioner on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. He was Chair of the 2011 NKF Spring Clinical Meeting and was the 2015 NKF Garabed Eknoyan Award Winner. Dr. Choi is currently a member of the American Board of Internal Medicine Nephrology Board Exam Committee. He was co-Editor of the Chronic Kidney Disease Section for the American Society of Nephrology (ASN) Self-Assessment Program and the ASN Post-Graduate Educational Committee.

Dr. Choi serves on the Editorial Board for the Clinical Journal of the American Society of Nephrology. He was co-Editor of the Oxford American Handbook of Clinical Medicine" and the Oxford Manual of Nephrology and Hypertension and Deputy Editor for Advances in Chronic Kidney Diseases.

He was an undergraduate at Yale University, and medical student and internal medicine resident at Johns Hopkins. He was a nephrology fellow at the University of Pennsylvania.

As of January 2017, Dr. Choi reported the following external relationships:

Service on data and safety monitoring boards for the following company, with compensation as listed:

  • GlaxoSmithKline, overseeing the safety of belimumab in trials of maintenance of remission in ANCA-associated glomerulonephritis and lupus nephritis, receiving reimbursement for travel expenses and honoraria.

Service on a research-related expert panel or advisory board for the following company, with compensation as listed:

  • AstraZeneca, receiving honoraria.

Work as an author or editor for following company, with compensation as listed:

  • Oxford University Press, receiving compensation as co-Editor for American Handbook of Clinical Medicine.

Dr. Choi serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • National Kidney Foundation, serving as President, receiving reimbursement for travel expenses.

Diane M. Cibrik, MD, MS

Dr. Cibrik is board certified in Nephrology. For 17 years, she has worked as a transplant nephrologist at the University of Michigan. She is now the Medical Director of Kidney and Pancreas Transplantation at the University of Kansas.

At the University of Michigan, Dr. Cibrik was Professor of Internal Medicine in the Division of Nephrology. She served as Medical Director of Clinical Trial Transplant Research and Pancreas Transplantation, and as a member on the Institutional Review Board. In addition, she was the Transplant Nephrology Fellowship Director.

Dr. Cibrik is a member of the American Board of Internal Medicine Nephrology Board Exam Committee. She has served on the Program Committee for the American Transplant Congress (ATC) as well as Chair for multiple transplant sessions and served on the ATC Education Committee. She was a reviewer for American Journal of Transplantation, Clinical Transplantation, and Journal of American Society of Nephrology. In addition, Dr. Cibrik has served as Principal Investigator on numerous clinical trials and served as Scientific Advisor for Novartis, Astellas, and Pfizer pharmaceuticals in the past.

Dr. Cibrik received a bachelor’s degree in chemistry from John Carroll University and a medical degree from Case Western Reserve University. She completed her internal medicine residency and nephrology and transplant fellowships at University Hospitals of Cleveland. She received a master’s degree in clinical research design and statistical analysis from the University of Michigan in 2001.

As of July 2017, Dr. Cibrik reported the following external relationships:

Funding for clinical trial expenses and staff, paid to The University of Michigan, from the following company:

  • Novartis, studying phase II trial of CFZ533 (an anti-CD40 monoclonal antibody) in kidney transplantation.

Bernard G. Jaar, MD

Dr. Jaar is in private practice with the Nephrology Center of Maryland in Baltimore and is an Assistant Professor of Medicine (part-time) in the Division of Nephrology, Department of Medicine at the Johns Hopkins School of Medicine with Joint Appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He is also an Associate Faculty Member of the Welch Center for Prevention, Epidemiology and Clinical Research at the Johns Hopkins Medical Institutions. He is board certified in Nephrology.

Dr. Jaar is a member of the American Board of Internal Medicine Nephrology Board Exam Committee. He has served on the editorial board of several nephrology journals and is currently the Section Editor for Epidemiology and Outcomes Research for BMC Nephrology. He is the immediate past Chair of the Medical Advisory Board and of the Grant Review Committee of the National Kidney Foundation of Maryland (NKFM). He is a member of the Board of Directors of the NKFM; he is also a member of National Kidney Foundation's Dialysis Outcomes Quality Initiative Education Committee. He is a member of the State of Maryland Commission on Kidney Disease and a Fellow of the American Society of Nephrology and of the National Kidney Foundation. He received the President's Award and Volunteer of Year Award from the NKFM. He also received the Section Editor of the Year Award (2014) from BioMed Central, London, England.

Dr. Jaar received his medical degree from the State University of Haiti. He completed house staff training at the Assistance Publique – Hôpitaux de Paris, in Paris, France and obtained a nephrology degree from Paris 5 Descartes University before moving to the United States. He completed again his house staff training in internal medicine at the Graduate Hospital in Philadelphia and a fellowship in nephrology at the Johns Hopkins Hospital in Baltimore. He holds a master of public health degree from the Johns Hopkins Bloomberg School of Public Health.

As of July 2017, Dr. Jaar reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • BioMed Central Nephrology, Section Editor, without compensation.
  • UpToDate, receiving compensation for authorship.

Dr. Jaar serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • National Kidney Foundation of Maryland, Member, Board of Directors; Immediate Past Chairman, Medical Advisory Board; and Immediate Past Chairman, Research Grant Committee, receiving no financial support.
  • National Kidney Foundation, Chair, Education Committee, receiving no financial support.
  • Kidney Commission for the State of Maryland, Chair, receiving no financial support.

William W. LeCates, MD

Dr. LeCates is a Senior Attending Physician in nephrology at the Bassett Medical Center in Cooperstown, New York, and a Clinical Assistant Professor of Medicine at the Columbia University College of Physicians and Surgeons. Since 2011, he has also served as the Medical Director of the Bassett Medical Center.

Previously, he was the Program Director for the Bassett Medical Center Internal Medicine Residency. He also served in the Unites States Army and is a veteran of Operation Enduring Freedom, Afghanistan, and Operation Onward Liberty, Liberia.

Dr. LeCates is a member of the American Board of Internal Medicine Nephrology Board Exam Committee. He is board certified in Internal Medicine and Nephrology.

Dr. LeCates was an undergraduate at Amherst College where he was elected to Phi Beta Kappa. He earned his medical degree from The Johns Hopkins University School of Medicine where he was elected to Alpha Omega Alpha. He completed internal medicine residency and nephrology fellowship training at The Johns Hopkins Hospital. He also served as an Assistant Chief of Service on the Osler Medical Service of the Johns Hopkins Hospital.

As of July 2017, Dr. LeCates reported no external relationships:

John C. Lieske, MD

Dr. Lieske, board certified in Internal Medicine and Nephrology, is Professor of Medicine at the Mayo Clinic College of Medicine, and the Director of the Renal Function Laboratory in the Department of Laboratory Medicine and Pathology at the Mayo Clinic. He is also Principal Investigator for the Mayo Clinic O'Brien Urology Research Center; Assistant Director for the Rare Kidney Stone Consortium and Director of the Dent Disease component; and Principal Investigator for the Mayo NIH Nephrology Training Grant.

He has a longstanding interest in urinary proteomics and nephrolithiasis, including NIH-funded projects to investigate inhibitors of crystal aggregation, growth and adhesion to tubular cells; epidemiology of nephrolithiasis; genetics of nephrolithiasis; and mechanisms of enteric hyperoxaluria. As Director of the Renal Function Lab, Dr. Lieske has also developed expertise regarding renal markers of renal disease, including tandem mass spectrometry-based assays for urinary biomarkers and validation of newer markers of injury and kidney function (e.g., cystatin C, NGAL). Dr. Lieske has previously conducted clinical trials regarding the role of diet and probiotics in patients with and without enteric hyperoxaluria. He has also studied the epidemiology of enteric hyperoxaluria and kidney disease after bariatric surgery.

From 1993 to 2000, Dr. Lieske was a faculty member at the University of Chicago before being recruited to Mayo Clinic in 2000.

He serves as a member of the American Board of Internal Medicine Nephrology Board Exam Committee.

Dr. Lieske earned a bachelor's degree in biomedical engineering at Northwestern University and his medical degree at the University of Chicago. He did fellowships at the University of Chicago in Research Nephrology and Clinical Nephrology, and residency training and internship at Emory University.

As of January 2017, Dr. Lieske reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Mayo Clinic, from the following companies:

  • Allena, study of an oxalate-degrading enzyme in hyperoxaluric kidney stone formers.
  • OxThera, for a trial of oxalobacter to treat primary hyperoxaluria.

Service on a research-related expert panel or advisory board, paid to the Mayo Clinic, for the following company, with compensation as listed:

  • Alnylam, providing advice on potential siRNA therapy for primary hyperoxaluria, receiving reimbursement for travel expenses and honoraria provided directly to

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities, paid to The Mayo Clinic, for the following company, with compensation as listed:

  • OxThera, providing advice regarding trial design and interpretation for hyperoxaluria receiving research funding provided to the Mayo Clinic.

Dr. Lieske serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Oxalosis and Hyperoxaluria Foundation, member of Scientific Advisory Board, receiving reimbursement for travel expenses.

Rajnish Mehrotra, MD

Dr. Mehrotra, board certified in Internal Medicine and Nephrology, is Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Chief of the Division of Nephrology and Hypertension at Harbor-UCLA Medical Center. He chairs the Dialysis Advisory Group of the American Society of Nephrology.

Dr. Mehrota is a member of the American Board of Internal Medicine Nephrology Board Exam Committee. He has been admitted to Alpha Omega Alpha, an honorary medical society, and was awarded the John Maher Award by the International Society for Peritoneal Dialysis in 2006. His research support includes, among others, grants from the National Institutes of Health and the American Heart Association. His research interests include determinants of selection of dialysis modality, outcome studies in peritoneal dialysis, and mineral metabolism in chronic kidney disease. Dr. Mehrota has published/co-authored over 120 articles and/or book chapters. He is an Associate Editor of NephSAP, Section Editor for Clinical Nephrology, and serves as a member of the editorial board of Journal of American Society of Nephrology, Kidney International, Clinical Journal of American Society of Nephrology, Peritoneal Dialysis International and Journal of Renal Nutrition. He chairs the Education Committee of the International Society for Peritoneal Dialysis and is a member of the Board of Directors for the International Society for Hemodialysis.

He received his medical degree from All India Institute of Medical Sciences. He completed his internship and residency training at the Medical College of Pennsylvania/Hahnemann University – Drexel University College of Medicine and fellowship training at the University of Missouri-Columbia.

As of January 2017, Dr. Mehrotra reported the following external relationships:

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • Baxter, to support Home Dialysis University, an educational course for practicing physicians to teach principles of peritoneal and home hemodialysis, receiving reimbursement for travel expenses and honoraria. Continuing medical education for this activity is provided by Wake Forest University.

Work as an author or editor for following companies, with compensation as listed:

  • American Society of Nephrology, Editor-in-Chief, Clinical Journal of the American Society of Nephrology, receiving a stipend.
  • Journal of Renal Nutrition, Editorial Board.
  • Kidney International, Editorial Board.

Dr. Mehrotra serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Nephrology, co-Chair of Clinical Research Course; co-Chair of KHI Workgroup on symptom prioritization; Member of Public Policy Board, reimbursement for travel expenses and honoraria paid directly to institution.
  • Dialysis Patient Citizens, Member, Education Board, receiving no compensation.
  • International Societu of Peritoneal Dialysis, Treasurer, President of North American Chapter, receiving no compensation.
  • Northwest Kidney Centers, Member Board of Trustees, receiving no compensation.

Dena Rifkin, MD

Dr. Rifkin, an Associate Professor at the University of California, San Diego, is a board certified internist and nephrologist. She serves as Director of Dialysis Services, VA San Diego Healthcare System.

Dr. Rifkin was previously an instructor at Tufts Medical School in Boston. Prior to that role, she was an instructor at Yale University School of Medicine, where she served as Chief Medical Resident.

Dr. Rifkin is a member of the American Board of Internal Medicine Nephrology Board Exam Committee. She serves as chair of the 2017 National Kidney Foundation Spring Clinical Meeting. She holds a K23 Mentored Patient-Oriented Research award from the National Institute of Diabetes and Digestive and Kidney Diseases focused on blood pressure patterns in the elderly, and an R03 award on cognition and blood pressure patterns. Dr. Rifkin recently received a U.S. Department of Veterans Affairs Merit Review Award for a clinical trial of self- management of hypertension.

She holds an undergraduate degree in computer science, magna cum laude, from Harvard University. Dr. Rifkin earned her medical degree from Yale University School of Medicine.

As of January 2017, Dr. Rifkin reported the following external relationships:

Dr. Rifkin serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • National Kidney Foundation, Program Chair for annual meeting, receiving reimbursement for travel expenses.